TrialESMO open2020

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.

Gerardo Colon-Otero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.